SCHEMBL2904656

SCHEMBL2904656

O/N=C\c1ccc(Cl)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
GRIN2D O15399 2/20 0.59
GRIN3B O60391 2/20 0.59
GRIN1 Q05586 2/20 0.59
GRIN2A Q12879 2/20 0.59
GRIN2B Q13224 2/20 0.59
GRIN2C Q14957 2/20 0.59
GRIN3A Q8TCU5 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
TDP1 Q9NUW8 1/20 0.54
AMY1A P0DUB6 1/20 0.53
HPGD P15428 3/20 0.50
TSHR P16473 2/20 0.50
GUSB P08236 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 2/20 0.46
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756954 1.00 MAPT (0.59) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2904660 1.00 MAPT (0.59) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4049047 1.00 MAPT (0.59) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5805555 0.83 TSHR (0.54) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5805553 0.83 TSHR (0.54) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30778025 0.83 TSHR (0.54) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7372200 0.81 TSHR (0.49) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17548943 0.81 TTR (0.63) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7372197 0.81 TSHR (0.49) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL16881403 0.79 HPGD (0.51) MAPTGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3746448-B1 NITROGENOUS TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2025-01-15 EP disclosed
US-12162843-B2 High-purity thermostable crystal form of substituted 3-isoxazolidinone compound, preparation method therefor and application thereof Zhejiang Zhuji United Chemicals Co., Ltd. (CN) 2024-12-10 US disclosed
US-20220089553-A1 HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Zhejiang Zhuji United Chemicals Co., Ltd. (CN) 2022-03-24 US disclosed
EP-3971170-A1 HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Zhejiang Zhuji United Chemicals Co., Ltd (CN) 2022-03-23 EP disclosed
US-11208418-B2 Nitrogenous tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-12-28 US disclosed
US-20200392146-A1 NITROGENOUS TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-12-17 US disclosed
US-9580444-B2 Polycyclic pyrazolinone derivative and herbicide comprising same as effective component thereof SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2017-02-28 US disclosed
US-20160024110-A1 POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-01-28 US disclosed
EP-2975040-A1 POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF Sagami Chemical Research Institute (JP) 2016-01-20 EP disclosed
CN-103588679-A Synthetic method for 2,4-dichlorobenzonitrile TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD 2014-02-19 CN disclosed
US-7790759-B2 Glycyrrhetinic acid-30-amide derivatives and their use TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2010-09-07 US disclosed
EP-1935892-B1 GLYCYRRHETINIC ACID-30-AMIDE DERIVATIVES AND THE USES THEREOF TIANJIN INST PHARM RESEARCH (CN) 2010-08-11 EP disclosed
US-20080214636-A1 Glycyrrhetinic Acid-30-Amide Derivatives and Their Use TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2008-09-04 US disclosed
EP-1935892-A1 GLYCYRRHETINIC ACID-30-AMIDE DERIVATIVES AND THE USES THEREOF TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) 2008-06-25 EP disclosed
US-4405357-A Herbicidal 3-isoxazolidinones and hydroxamic acids FMC CORPORATION (US) 1983-09-20 US disclosed
US-4283403-A Substituted isoxazolines for control of plant phytopathogens ELI LILLY AND COMPANY (US) 1981-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162843-B2 High-purity thermostable crystal form of substituted 3-isoxazolidinone compound, preparation method therefor and application thereof CYP51A1, WEE2, WEE1 MAPT 4145/4885GRIN2D 2082/4885GRIN3B 3449/4885
US-20160024110-A1 POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF DDT, PDHX, CYP4X1 MAPT 4308/4885GRIN2D 549/4885GRIN3B 919/4885
US-20200392146-A1 NITROGENOUS TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE NR1H4, SLC10A1, FXR1 MAPT 148/4885GRIN2D 2474/4885GRIN3B 1183/4885
US-20220089553-A1 HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CYP51A1, WEE2, WEE1 MAPT 4145/4885GRIN2D 2082/4885GRIN3B 3449/4885
US-11208418-B2 Nitrogenous tricyclic compounds and uses thereof in medicine NR1H4, SLC10A1, FXR1 MAPT 148/4885GRIN2D 2474/4885GRIN3B 1183/4885
US-20080214636-A1 Glycyrrhetinic Acid-30-Amide Derivatives and Their Use IL36G, CYP26A1, IL17A MAPT 1573/4885GRIN2D 1738/4885GRIN3B 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.